edoc

Allogeneic hematopoietic SCT for patients with autoimmune diseases

Daikeler, T. and Hügle, T. and Farge, D. and Andolina, M. and Gualandi, F. and Baldomero, H. and Bocelli-Tyndall, C. and Brune, M. and Dalle, J. H. and Urban, C. and Ehninger, G. and Gibson, B. and Linder, B. and Lioure, B. and Marmont, A. and Matthes-Martin, S. and Nachbaur, D. and Schuetz, P. and Tyndall, A. and van Laar, J. M. and Veys, P. and Saccardi, R. and Gratwohl, A.. (2009) Allogeneic hematopoietic SCT for patients with autoimmune diseases. Biology of blood and marrow transplantation : official journal of the American Society for Blood and Marrow Transplantation, Vol. 44. pp. 27-33.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/dok/A6006286

Downloads: Statistics Overview

Abstract

Allogeneic hematopoietic SCT (HSCT) has been used as treatment for single patients with autoimmune diseases (AD). To summarise currently available information, we analyzed all patients who underwent allogeneic HSCT for AD and who reported to the European Group for Blood and Marrow Transplantation (EBMT) database. Thirty-five patients receiving 38 allogeneic transplantations for various hematological and non-hematological AD were identified. Four patients had had an allogeneic HSCT for a conventional hematological indication in the past. Fifty-five per cent of the transplantation procedures led to a complete clinical response of the refractory AD and 23% to at least a partial response. The median duration of response at the last follow-up was 70.7 (15.2-130) months. Three patients relapsed at a median of 12.3 months after HSCT. Treatment-related mortality at 2 years was 22.1% (95% CI: 7.3-36.9%). Two deaths were caused by progression of AD. The probability of survival at 2 years was 70%. No single factor predicting the outcome could be identified. The retrospective nature of this study and the heterogeneous, partly incomplete data are its limitations. However, allogeneic HSCT can induce remission in patients suffering from refractory AD. These data provide the basis for carefully conducted prospective trials.
Faculties and Departments:03 Faculty of Medicine > Bereich Medizinische Fächer (Klinik) > Ehemalige Einheiten Medizinische Fächer (Klinik) > Rheumatologie FPS (Tyndall)
03 Faculty of Medicine > Departement Klinische Forschung > Bereich Medizinische Fächer (Klinik) > Ehemalige Einheiten Medizinische Fächer (Klinik) > Rheumatologie FPS (Tyndall)
03 Faculty of Medicine > Departement Biomedizin > Former Units at DBM > Rheumatologie FPS (Tyndall)
03 Faculty of Medicine > Bereich Medizinische Fächer (Klinik) > Ehemalige Einheiten Medizinische Fächer (Klinik) > Hämatologie (Gratwohl)
03 Faculty of Medicine > Departement Klinische Forschung > Bereich Medizinische Fächer (Klinik) > Ehemalige Einheiten Medizinische Fächer (Klinik) > Hämatologie (Gratwohl)
UniBasel Contributors:De Vere-Tyndall, Alan and Gratwohl, Alois A.
Item Type:Article, refereed
Article Subtype:Research Article
Bibsysno:Link to catalogue
Publisher:Elsevier
ISSN:1083-8791
Note:Publication type according to Uni Basel Research Database: Journal article
Related URLs:
Identification Number:
Last Modified:01 Feb 2013 08:46
Deposited On:01 Feb 2013 08:45

Repository Staff Only: item control page